

# Mitchell S Cairo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3389345/publications.pdf>

Version: 2024-02-01

287  
papers

12,813  
citations

30551

56  
h-index

33145

104  
g-index

292  
all docs

292  
docs citations

292  
times ranked

11206  
citing authors

#	ARTICLE	IF	CITATIONS
1	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
2	Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience. <i>Bone Marrow Transplantation</i> , 2022, 57, 445-452.	1.3	3
3	Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	1
4	The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). <i>Current Treatment Options in Oncology</i> , 2022, 23, 381-403.	1.3	5
5	Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin's lymphoma: a phase II, non-randomized controlled trial. , 2022, 10, e004445.		5
6	KIR-favorable TCR- $\alpha\beta$ /CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. <i>Blood</i> , 2022, 140, 2556-2572.	0.6	9
7	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
8	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 177.e1-177.e8.	0.6	16
9	Haematopoietic progenitor cell transplantation in adults with symptomatic sickle cell disease: the time has arrived. <i>British Journal of Haematology</i> , 2021, 192, 678-680.	1.2	0
10	A Pilot Study of RNA Sequencing to Improve the Diagnostic Yield of Bronchoalveolar Lavage Specimens in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Respiration</i> , 2021, 100, 356-363.	1.2	0
11	Human Cord Blood Derived Unrestricted Somatic Stem Cells Restore Aquaporin Channel Expression, Reduce Inflammation and Inhibit the Development of Hydrocephalus After Experimentally Induced Perinatal Intraventricular Hemorrhage. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 633185.	1.8	13
12	Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2221-2230.	1.3	10
13	A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2994-2997.	3.3	7
14	Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. , 2021, 9, e002267.		14
15	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	0.6	15
16	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021, 17, 3549-3560.	1.1	10
17	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	1.3	13
18	The Safety and Efficacy of Granulocyte Transfusions in Pediatric Recipients with Severe Neutropenia. <i>Blood</i> , 2021, 138, 2148-2148.	0.6	3

#	ARTICLE	IF	CITATIONS
19	<i>IFN-<math>\gamma</math> Inhibitors and Ruxolitinib Therapy for Acquired Severe Aplastic Anemia in an Ex-Vivo Model</i> . Blood, 2021, 138, 1123-1123.	0.6	0
20	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood, 2021, 138, 3134-3134.	0.6	1
21	First Reported Case Series of Concomitant Ruxolitinib and Ibrutinib for Graft-Versus-Host Disease (GVHD). Blood, 2021, 138, 4885-4885.	0.6	2
22	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 3880-3880.	0.6	4
23	Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease. JAMA Pediatrics, 2020, 174, 195.	3.3	25
24	Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. Seminars in Hematology, 2020, 57, 201-212.	1.8	17
25	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Advances, 2020, 4, 3180-3190.	2.5	18
26	Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma. , 2020, 8, e001238.		11
27	Black Lives and Black Donors Matter Post-Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e245-e246.	2.0	0
28	Pralatrexate-based therapy induced response in an adolescent with refractory hepatosplenic T-cell lymphoma. Pediatric Blood and Cancer, 2020, 67, e28460.	0.8	2
29	Exposed CendR Domain in Homing Peptide Yields Skin-Targeted Therapeutic in Epidermolysis Bullosa. Molecular Therapy, 2020, 28, 1833-1845.	3.7	17
30	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 2020, 105, 1329-1338.	1.7	23
31	Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation. British Journal of Haematology, 2020, 190, 822-836.	1.2	53
32	Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy. Leukemia, 2020, 34, 2271-2275.	3.3	9
33	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. British Journal of Haematology, 2020, 190, 573-582.	1.2	19
34	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer, 2020, 126, 2279-2287.	2.0	17
35	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
36	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11

#	ARTICLE	IF	CITATIONS
37	Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma. <i>Oncotarget</i> , 2020, 11, 1691-1704.	0.8	6
38	Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL. <i>Oncotarget</i> , 2020, 11, 3035-3047.	0.8	4
39	Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1135-1142.	2.3	0
40	Preliminary Results of a Phase II Study to Determine the Safety of Defibrotide in Children and Adolescents with Sickle Cell Disease-Associated Acute Chest Syndrome (IND 127812). <i>Blood</i> , 2020, 136, 8-9.	0.6	0
41	Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449). <i>Blood</i> , 2020, 136, 2-4.	0.6	1
42	Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359). <i>Blood</i> , 2020, 136, 20-21.	0.6	0
43	Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL). <i>Blood</i> , 2020, 136, 23-24.	0.6	1
44	Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2020, 136, 3-4.	0.6	0
45	Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases. <i>Blood</i> , 2020, 136, 32-33.	0.6	0
46	The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 226-235.	1.3	5
47	Excellent outcomes in children and adolescents with CNS Burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1. <i>British Journal of Haematology</i> , 2019, 185, 374-377.	1.2	23
48	Human Cord Blood-Derived Unrestricted Somatic Stem Cell Infusion Improves Neurobehavioral Outcome in a Rabbit Model of Intraventricular Hemorrhage. <i>Stem Cells Translational Medicine</i> , 2019, 8, 1157-1169.	1.6	22
49	Late Health Outcomes After Contemporary Lymphoma Malin de Burkitt Therapy for Mature B-Cell Non-Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2556-2570.	0.8	17
50	Surveillance imaging in pediatric lymphoma. <i>Pediatric Radiology</i> , 2019, 49, 1565-1573.	1.1	8
51	Immunotherapeutic Challenges for Pediatric Cancers. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 38-48.	2.0	26
52	Mature (non-nodular, non-cutaneous) T-NK cell lymphomas in children, adolescents and young adults: state of the science. <i>British Journal of Haematology</i> , 2019, 185, 418-435.	1.2	9
53	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
54	Rituximab in the treatment of childhood mature B-cell lymphoma: "Where do we go from here". <i>British Journal of Haematology</i> , 2019, 185, 1017-1020.	1.2	5

#	ARTICLE	IF	CITATIONS
55	Prognostic Factors in Childhood and Adolescent Non-Hodgkin Lymphoma. , 2019, , 131-149.		2
56	Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56 <sup>+</sup> Dim <sup>-</sup> NK cells. <i>Innate Immunity</i> , 2019, 25, 294-304.	1.1	8
57	IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27770.	0.8	21
58	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
59	Assessment of Safety and Efficacy of PBSC Mobilization with G-CSF and CD34+ Enrichment and Pbmnc (CD3+) Addback in Familial Haploidentical (FHI) Adult Donors with Sickle Cell Disease Trait (SCDT) Prior to Allogeneic HSCT of High-Risk SCD Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S310.	2.0	3
60	A new Burkitt-like lymphoma. <i>Blood</i> , 2019, 133, 889-891.	0.6	1
61	Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives. <i>British Journal of Haematology</i> , 2019, 185, 1021-1042.	1.2	37
62	Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 51.	1.3	117
63	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
64	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89
65	Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1055-1070.	1.2	16
66	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, <i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. <i>Oncotarget</i> , 2019, 8, e1512455.	2.1	17
67	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
68	Incidence and outcomes of rare paediatric non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , 2019, 184, 864-867.	1.2	9
69	Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 3963-3963.	0.6	3
70	A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents. <i>Blood</i> , 2019, 134, 2443-2443.	0.6	5
71	Resistance to Bruton's Tyrosine Kinase Signaling Pathway Targeted Therapies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 111-153.	0.1	1
72	Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7036-7036.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 4624-4624.	0.6	0
74	Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 127-127.	0.6	0
75	Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359). <i>Blood</i> , 2019, 134, 1990-1990.	0.6	0
76	Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27091.	0.8	4
77	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
78	Monoclonal Antibodies Targeting Hematological Malignancies. , 2018, , 79-116.		0
79	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27034.	0.8	26
80	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34
81	Ruxolitinib significantly enhances <i>in vitro</i> apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. <i>Oncotarget</i> , 2018, 9, 9776-9788.	0.8	17
82	Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. <i>Oncotarget</i> , 2018, 9, 21820-21830.	0.8	24
83	Lymphoma in Adolescents and Young Adults. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 285-300.	1.0	7
84	Cord Blood-Derived Stem Cells Suppress Fibrosis and May Prevent Malignant Progression in Recessive Dystrophic Epidermolysis Bullosa. <i>Stem Cells</i> , 2018, 36, 1839-1850.	1.4	15
85	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	2.5	13
86	Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. <i>British Journal of Haematology</i> , 2018, 182, 859-869.	1.2	41
87	Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic) Tj ETQq1 1 0.784314 rgBT/Qverlock 10	1.6	8
88	NHL in adolescents and young adults: A unique population. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27073.	0.8	19
89	Therapeutic effects of 2B8T2M, a novel fusion of ALT-803, an IL-15 superagonist, with 4 single-chains of anti-CD20 antibody in combination with expanded natural killer cells against rituximab sensitive and resistant Burkitt lymphoma (BL).. <i>Journal of Clinical Oncology</i> , 2018, 36, 32-32.	0.8	0
90	Developing educational interventions and clinical tools to improve risk-based prevention and management of tumor lysis syndrome (TLS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e18811-e18811.	0.8	0



#	ARTICLE	IF	CITATIONS
91	Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2017, 177, 601-611.	1.2	15
92	A Pilot Trial of Unrelated Donor Human Placenta-Derived Stem Cells (HPDSC) in Conjunction with Single Unrelated Cord Blood Transplantation (UCBT) in Children with Malignant and Non-Malignant Disease (IND 14949). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S121.	2.0	2
93	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
94	A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 173-178.	0.2	26
95	Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma <i>in vitro</i> and in immunodeficient mice. <i>Oncolmmunology</i> , 2017, 6, e1341031.	2.1	61
96	Non-Hodgkin Lymphoma. <i>Pediatric Oncology</i> , 2017, , 69-117.	0.5	2
97	Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy. <i>Experimental Hematology</i> , 2017, 46, 38-47.	0.2	18
98	The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. <i>Oncotarget</i> , 2017, 8, 27839-27853.	0.8	31
99	High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation. <i>Oncotarget</i> , 2017, 8, 110350-110357.	0.8	33
100	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. <i>Oncotarget</i> , 2017, 8, 113895-113909.	0.8	15
101	Risk-adapted therapy utilizing upfront brentuximab vedotin (Bv) and rituximab (R) with reduced toxicity chemotherapy in children, adolescents, and young adults with Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10532-10532.	0.8	0
102	The evolution of allogeneic stem cell transplant for children and adolescents with acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 52-62.	0.3	10
103	Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. <i>British Journal of Haematology</i> , 2016, 173, 503-504.	1.2	11
104	Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 597-616.	1.2	16
105	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
106	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
107	Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy. <i>Methods in Molecular Biology</i> , 2016, 1441, 215-230.	0.4	6
108	Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science. <i>British Journal of Haematology</i> , 2016, 173, 507-530.	1.2	30

#	ARTICLE	IF	CITATIONS
109	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
110	A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33 + Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 698-704.	2.0	22
111	Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells. <i>Blood</i> , 2016, 128, 2944-2944.	0.6	1
112	Preliminary results of a reduced burden of therapy trial by incorporation of rituximab and intrathecal liposomal cytarabine in children, adolescents and young adults with intermediate (FAB) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 2016, 34, 10534-10534.	0.8	4
113	Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10533-10533.	0.8	0
114	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
115	Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report. <i>British Journal of Haematology</i> , 2015, 170, 367-371.	1.2	12
116	Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015, 171, 763-775.	1.2	83
117	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1171-1175.	0.8	89
118	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
119	Impact of Pretransplantation 18F-fluorodeoxy Glucose Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
120	Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Pediatrics</i> , 2015, 167, 765-769.e1.	0.9	25
121	Differential proteomic analysis of endemic and sporadic Epstein-Barr virus-positive and negative Burkitt lymphoma. <i>European Journal of Cancer</i> , 2015, 51, 92-100.	1.3	14
122	Rescue of the Mucocutaneous Manifestations by Human Cord Blood Derived Nonhematopoietic Stem Cells in a Mouse Model of Recessive Dystrophic Epidermolysis Bullosa. <i>Stem Cells</i> , 2015, 33, 1807-1817.	1.4	17
123	MicroRNA-146a and MicroRNA-146b Regulate Human Dendritic Cell Apoptosis and Cytokine Production by Targeting TRAF6 and IRAK1 Proteins. <i>Journal of Biological Chemistry</i> , 2015, 290, 2831-2841.	1.6	206
124	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
125	Revised International Pediatric Non-Hodgkin Lymphoma Staging System. <i>Journal of Clinical Oncology</i> , 2015, 33, 2112-2118.	0.8	150
126	International Pediatric Non-Hodgkin Lymphoma Response Criteria. <i>Journal of Clinical Oncology</i> , 2015, 33, 2106-2111.	0.8	64



#	ARTICLE	IF	CITATIONS
127	Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice. <i>Cancer Immunology Research</i> , 2015, 3, 333-344.	1.6	138
128	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. <i>Journal of Clinical Oncology</i> , 2015, 33, 2963-2974.	0.8	202
129	A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors. <i>Pediatric Blood and Cancer</i> , 2015, 62, 274-278.	0.8	2
130	Hematopoietic stem cell transplantation for sickle cell disease: state of the science. <i>European Journal of Haematology</i> , 2015, 94, 391-399.	1.1	38
131	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2020-2028.	3.2	98
132	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. <i>PLoS ONE</i> , 2015, 10, e0133152.	1.1	78
133	Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL. <i>Blood</i> , 2015, 126, 2732-2732.	0.6	0
134	A Pilot Study of Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia. <i>Blood</i> , 2015, 126, 2499-2499.	0.6	0
135	Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 113-23.	0.3	18
136	Targeting Glutathione S-transferase M4 in Ewing sarcoma. <i>Frontiers in Pediatrics</i> , 2014, 2, 83.	0.9	18
137	Smoothing the crescent curve: sickle cell disease. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 468-474.	0.9	7
138	Childhood and Adolescent B-Cell Lymphoma: Bench to Bedside and Back to Bench. , 2014, , 247-285.		0
139	Humoral and Cellular Immunotherapy in ALL in Children, Adolescents, and Young Adults. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S6-S13.	0.2	8
140	Familial Haploidentical (FHI) T-Cell Depleted (TCD) with T-Cell Addback Stem Cell Transplantation for Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S135-S136.	2.0	2
141	Expression of Notch1 and mTOR pathway proteins in pediatric lymphoblastic lymphoma; a Children's Oncology Group report. <i>Journal of Hematopathology</i> , 2014, 7, 9-14.	0.2	1
142	A Comparison of Bronchoalveolar Lavage versus Lung Biopsy in Pediatric Recipients after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1229-1237.	2.0	29
143	Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1289-1294.	0.8	11
144	Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive <sc>B</sc>urkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>British Journal of Haematology</i> , 2014, 167, 394-401.	1.2	113

#	ARTICLE	IF	CITATIONS
145	Reduced Intensity Conditioning and Hematopoietic Stem Cell Transplantation in Pediatric Nonmalignant Disease: A New Therapeutic Paradigm. <i>Journal of Pediatrics</i> , 2014, 164, 952-953.e2.	0.9	5
146	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
147	Allotransplantation for Patients Age $\leq$ 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
148	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
149	Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. <i>Cytotherapy</i> , 2014, 16, 1431-1440.	0.3	25
150	Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. <i>Blood</i> , 2014, 123, 1615-1620.	0.6	56
151	Human Cord Blood-Derived Unrestricted Somatic Stem Cells Promote Wound Healing and have Therapeutic Potential for Patients with Recessive Dystrophic Epidermolysis Bullosa. <i>Cell Transplantation</i> , 2014, 23, 303-317.	1.2	42
152	Deregulation of the PI3K/Akt Signal Transduction Pathway Is Associated with the Development of Chemotherapy Resistance and Can be Effectively Targeted to Improve Chemosensitiveness in Burkitt Lymphoma Pre-Clinical Models. <i>Blood</i> , 2014, 124, 1769-1769.	0.6	3
153	Mir-146a and Mir-146b Regulate Human Dendritic Cell Apoptosis and Cytokine Production By Targeting of TRAF6 and IRAK1. <i>Blood</i> , 2014, 124, 4118-4118.	0.6	0
154	Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2013, 161, 27-42.	1.2	28
155	Rituximab pharmacokinetics in children and adolescents with <i>de novo</i> intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2013, 162, 678-683.	1.2	31
156	Low Dose Liposomal Amphotericin B Followed by Micafungin Prophylaxis of Invasive Fungal Infections (IFI) in Pediatric Allogeneic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S262.	2.0	1
157	Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. <i>Blood</i> , 2013, 121, 278-285.	0.6	80
158	Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-cell NHL: a Children's Oncology Group Report. <i>British Journal of Haematology</i> , 2013, 163, 365-372.	1.2	49
159	Transplantation-Related Mortality, Graft Failure, and Survival after Reduced-Toxicity Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation in 100 Consecutive Pediatric Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 552-561.	2.0	70
160	Reduced Toxicity Conditioning with Busulfan, Fludarabine, Alemtuzumab and Allogeneic Stem Cell Transplantation From HLA-Matched Sibling Donors in Children with High Risk Sickle Cell Disease Results in Long Term Donor Chimerism and Low Incidence of aGVHD. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S164-S165.	2.0	1
161	Advances in Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S38-S43.	2.0	6
162	Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children with Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 676-677.	2.0	45

#	ARTICLE	IF	CITATIONS
163	A pediatric translational perspective on the entity "progressive transformation of germinal centers (PTGC)" Pediatric Blood and Cancer, 2013, 60, 3-4.	0.8	8
164	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 3100-3109.	0.8	206
165	Obinutuzumab (GA101) Significantly Improves Survival In CD20 Positive Pre-B Cell Lymphoblastic Leukemia (pre-B-ALL) Xenograft Models Compared To Rituximab (RTX): Potential Targeted Therapy In Patients With High Risk Pre-B-ALL. Blood, 2013, 122, 3068-3068.	0.6	3
166	Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Burkitt Lymphoma (BL) Regression and Improve Survival In Human BL Xenografted NSG Mice. Blood, 2013, 122, 3263-3263.	0.6	4
167	Overexpression Of Deleted In Lymphocytic Leukemia 1 (DLEU1) Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Primary Mediastinal B-Cell Lymphoma (PMBL): DLEU1 May Be a Tumor Suppressor Gene In a Subset Of Patients With PMBL. Blood, 2013, 122, 3852-3852.	0.6	2
168	The Acquisition Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models. Blood, 2013, 122, 5144-5144.	0.6	1
169	Obinutuzumab (GA101), a Novel Type II Glycoengineered CD20 Antibody, Significantly Induced Programmed Cell Death In Primary Mediastinal B-Cell Lymphoma (PMBL): Obinutuzumab May Be a Future Potential Targeted Agent For The Treatment Of PMBL. Blood, 2013, 122, 5146-5146.	0.6	1
170	Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukemia: A Children's Oncology Group (COG) report.. Journal of Clinical Oncology, 2013, 31, 3055-3055.	0.8	0
171	Sequence-Specific Talens-Induced DLEU1 Gene Disruption Significantly Suppresses Apoptosis and Increases Phosphorylation Of AKT and Ikbα In Pediatric Burkitt Lymphoma (PBL): DLEU1 May Act As a Tumor Suppressor Gene In PBL. Blood, 2013, 122, 1279-1279.	0.6	0
172	Exogenous Overexpression Of DLEU1 Significantly Induces Programmed Cell Death and Inhibits Cell Proliferation In Burkitt Lymphoma (BL) and Sensitizes Rituximab (RTX) Resistant BL Cells To RTX Induced Apoptosis. Blood, 2013, 122, 2503-2503.	0.6	0
173	Transcription Activator Like Effector Nucleases (TALENs) Mediated CD20 Gene Knockout Burkitt Lymphoma Model. Blood, 2013, 122, 4883-4883.	0.6	0
174	Global Phosphoproteomics Analysis Of Burkitt Lymphoma (BL) Demonstrates Abnormal Protein Phosphorylation In BCR, Spliceosome, mTOR and Chemokine Signaling Pathways In Rituximab Induced Resistant BL. Blood, 2013, 122, 928-928.	0.6	0
175	The future role of monoclonal antibody therapy in childhood acute leukaemias. British Journal of Haematology, 2012, 159, 3-17.	1.2	20
176	Advanced Stage, Increased Lactate Dehydrogenase, and Primary Site, but Not Adolescent Age (≥ 15) Tj ETQq0 0 0 rgBT /Overlock 10 Mature B-Cell Non-Hodgkin's Lymphoma: Results of the FAB LMB 96 Study. Journal of Clinical Oncology, 2012, 30, 387-393.	0.8	151
177	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood, 2012, 119, 3757-3766.	0.6	72
178	A Phase I Study of Gemtuzumab Ozogamicin (GO) in Combination with Busulfan and Cyclophosphamide (Bu/Cy) and Allogeneic Stem Cell Transplantation in Children with Poor-Risk CD33+ AML: A New Targeted Immunochemotherapy Myeloablative Conditioning (MAC) Regimen. Biology of Blood and Marrow Transplantation, 2012, 18, 324-329.	2.0	33
179	The immunophenotype of T lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. British Journal of Haematology, 2012, 159, 454-461.	1.2	74
180	Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality. British Journal of Haematology, 2012, 156, 99-108.	1.2	25

#	ARTICLE	IF	CITATIONS
181	Risk factors and treatment of childhood and adolescent <scp>B</scp>urkitt lymphoma/leukaemia. British Journal of Haematology, 2012, 156, 730-743.	1.2	70
182	Starry sky. British Journal of Haematology, 2012, 156, 783-783.	1.2	1
183	T cell depletion utilizing <scp>CD</scp>34<sup>+</sup> stem cell selection and <scp>CD</scp>3<sup>+</sup> addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients. British Journal of Haematology, 2012, 157, 205-219.	1.2	35
184	Abstract 516: Obinutuzumab (GA101): A novel type II glycoengineered CD20 antibody exhibits enhanced cell death against Rituximab-resistant and -sensitive cell lines in B-cell non-Hodgkin lymphoma. , 2012, , .		2
185	Incidence of Treatment-Related, Laboratory and Clinical Tumor Lysis Syndrome. Blood, 2012, 120, 238-238.	0.6	10
186	Expanded Natural Killer (NK) Cells Transfected with Anti-CD20 Chimeric Antigen Receptor (CAR) mRNA Have Significant Cytotoxicity Against Poor Risk B-Cell (CD20+) Leukemia/Lymphoma (B-L/L).. Blood, 2012, 120, 3007-3007.	0.6	40
187	Obinutuzumab (GA101) Significantly Enhances Cell Death and ADCC Compared to Rituximab Against CD20+ sensitive and Rituximab Resistant B-Cell Non-Hodgkin Lymphoma (NHL) and Lymphoblastic Leukemia (BLL). Blood, 2012, 120, 4865-4865.	0.6	1
188	JAK1/JAK2 Inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-Cell Lymphomas (PMBL). Blood, 2012, 120, 4886-4886.	0.6	3
189	Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2012, 30, 9501-9501.	0.8	2
190	Effect of obinutuzumab (GA101), a type II glycoengineered monoclonal antibody targeting CD20, against rituximab resistant and sensitive cell lines in B-cell non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2012, 30, e21150-e21150.	0.8	0
191	Low day 100 transplant-related mortality (TRM) and relapse rate following clofarabine (CLO) in combination with cytarabine, total body irradiation (TBI), and allogeneic stem cell transplantation (AlloSCT) in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.. Journal of Clinical Oncology, 2012, 30, 6537-6537.	0.8	0
192	Genetically engineered natural killer (NK) cell immunotherapy for children poor risk b-cell (CD20+) leukemia and lymphoma (L/L).. Journal of Clinical Oncology, 2012, 30, e13022-e13022.	0.8	0
193	Reprogramming and Characterization of Cord Blood Derived Stem Cells by Synthetic mRNAs: Potential for Cord Blood Stem Cell Regenerative Therapy. Blood, 2012, 120, 4748-4748.	0.6	0
194	Talens-Mediated DLEU1 Gene Silencing in Burkitt Lymphoma (BL): Implication of Lncrna DLEU1 Gene As a Potential Tumor Suppressor Gene in BL.. Blood, 2012, 120, 2403-2403.	0.6	0
195	Overexpression of Deleted Lymphocytic Leukemia 1 (DLEU1) Inhibits Proliferation of Burkitt Lymphoma (BL).. Blood, 2012, 120, 2654-2654.	0.6	0
196	Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Childrenâ€™s Oncology Group Study A5962. Biology of Blood and Marrow Transplantation, 2011, 17, 249-258.	2.0	58
197	Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2011, 17, 1375-1382.	2.0	188
198	Risk Factors Associated with Kidney Injury and the Impact of Kidney Injury on Overall Survival in Pediatric Recipients Following Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2011, 17, 1472-1480.	2.0	32

#	ARTICLE	IF	CITATIONS
199	Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1833-1840.	2.0	13
200	Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage) Tj ETQq0 0 0 rgBT /Overlock 1 <i>Haematology</i> , 2011, 153, 758-763.	1.2	32
201	A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning <i>versus</i> reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. <i>British Journal of Haematology</i> , 2011, 155, 218-234.	1.2	52
202	Cord blood transplantation and stem cell regenerative potential. <i>Experimental Hematology</i> , 2011, 39, 393-412.	0.2	53
203	Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 8797-8802.	3.3	252
204	The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM+ and CNS+ Mature B-NHL: A Children's Oncology Group Report. <i>Blood</i> , 2011, 118, 2702-2702.	0.6	4
205	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. <i>Blood</i> , 2011, 118, 573-573.	0.6	21
206	Genetically Engineered Natural Killer (NK) Cell Immunotherapy for Poor Risk B-Cell (CD20+) Leukemia and Lymphoma. <i>Blood</i> , 2011, 118, 1003-1003.	0.6	0
207	Safety of Liposomal Cytarabine Prophylaxis in Pediatric Bone Marrow Transplant (BMT) Recipients with Acute Leukemia (AL) and Non Hodgkin Lymphoma (NHL) At High Risk of CNS Relapse. <i>Blood</i> , 2011, 118, 4249-4249.	0.6	0
208	Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience. <i>Blood</i> , 2011, 118, 3074-3074.	0.6	0
209	Reduced Intensity or Non-Ablative Hematopoietic Cell Transplantation in Older Patients with Non-Hodgkin Lymphoma (NHL): Encouraging Survival for Patients >=55 Years. <i>Blood</i> , 2011, 118, 1015-1015.	0.6	0
210	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. <i>Blood</i> , 2011, 118, 3094-3094.	0.6	0
211	Genomic Pathways and Potential Therapeutic Targets in Pediatric Burkitt Lymphoma (PBL): A Children's Oncology Group Report. <i>Blood</i> , 2011, 118, 1587-1587.	0.6	1
212	Human Umbilical Cord Blood (HUCB) Derived Pluripotent Stem Cells Enhances Wound Healing. <i>Blood</i> , 2011, 118, 4824-4824.	0.6	0
213	Reduced-Toxicity (RTC) Versus Myeloablative Conditioning (MAC) Prior to Allogeneic Stem Cell Transplantation in Pediatric Participants: Significant Improvement in Physical Functioning Following RTC Versus MAC. <i>Blood</i> , 2011, 118, 2069-2069.	0.6	8
214	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010, 116, 4007-4015.	0.6	105
215	An increased frequency of 13q deletions detected by fluorescence <i>in situ</i> hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. <i>British Journal of Haematology</i> , 2010, 148, 600-610.	1.2	59
216	Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. <i>British Journal of Haematology</i> , 2010, 149, 578-586.	1.2	450



#	ARTICLE	IF	CITATIONS
217	Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure. <i>Journal of Clinical Oncology</i> , 2010, 28, 3730-3738.	0.8	386
218	Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 223-230.	2.0	144
219	An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 333-343.	2.0	52
220	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 709-728.	2.0	34
221	Bone Marrow Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa. <i>Dermatologic Clinics</i> , 2010, 28, 371-382.	1.0	31
222	Unrelated Umbilical Cord Blood Transplantation and Immune Reconstitution. <i>Seminars in Hematology</i> , 2010, 47, 22-36.	1.8	63
223	Dose Escalation of Clofarabine In Combination with Cytarabine and Total Body Irradiation (TBI) Followed by Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents and Young Adults (CAYA) with Poor-Risk Acute Leukemia. <i>Blood</i> , 2010, 116, 36-36.	0.6	2
224	Comparative Genomic Identification of Unique Signal Transduction Pathways and Targets In Pediatric Burkitt Lymphoma (PBL). <i>Blood</i> , 2010, 116, 631-631.	0.6	9
225	Romedepsin (RM), a Histone Deacetylase Inhibitor (HDACi), Significantly Increases the Expression of NKG2D Ligands, MIC A/B, In Pediatric Leukemia/Lymphoma Cells (LL), Resulting In Enhanced In Vitro and In Vivo NK Cytotoxicity In NOD-SCID Mice: Translational Approach for Adoptive NK Cell Targeted Immunotherapy. <i>Blood</i> , 2010, 116, 4297-4297.	0.6	6
226	Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: Implications for adoptive cellular immunotherapy. <i>Experimental Hematology</i> , 2009, 37, 1216-1229.	0.2	34
227	Differential gene expression signatures of adult peripheral blood vs cord blood monocyte-derived immature and mature dendritic cells. <i>Experimental Hematology</i> , 2009, 37, 1201-1215.	0.2	19
228	A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2009, 52, 177-181.	0.8	158
229	Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. <i>British Journal of Haematology</i> , 2009, 144, 24-40.	1.2	106
230	Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioning. <i>Pediatric Transplantation</i> , 2009, 13, 464-474.	0.5	21
231	Incidence of Viral and Fungal Infections following Busulfan-Based Reduced-Intensity versus Myeloablative Conditioning in Pediatric Allogeneic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1587-1595.	2.0	33
232	Hematopoietic Stem Cell Transplantation in Children and Adolescents with Malignant Disease. <i>Cancer Treatment and Research</i> , 2009, 144, 455-496.	0.2	0
233	Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2008, 50, 325-330.	0.8	60
234	Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1-8.	0.8	52



#	ARTICLE	IF	CITATIONS
235	Central neurocytoma responsive to topotecan, ifosfamide, carboplatin. <i>Pediatric Blood and Cancer</i> , 2008, 51, 137-140.	0.8	25
236	Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: Report of the French-American-British (FAB) international study group. <i>Pediatric Blood and Cancer</i> , 2008, 51, 369-374.	0.8	84
237	Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study*. <i>British Journal of Haematology</i> , 2008, 141, 840-847.	1.2	170
238	Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2008, 143, 261-267.	1.2	52
239	A Comparison of Inpatient Length of Stay and Costs Among Patients with Hematologic Malignancies (Excluding Hodgkin Disease) Associated with and Without Acute Renal Failure. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 44-51.	1.4	47
240	Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 44-53.	2.0	37
241	Tumor lysis syndrome: current perspective. <i>Haematologica</i> , 2008, 93, 9-13.	1.7	104
242	Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review. <i>Journal of Clinical Oncology</i> , 2008, 26, 2767-2778.	0.8	637
243	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3756-3762.	0.8	211
244	A photographic fishing expedition with granite. <i>Blood</i> , 2008, 111, 4-5.	0.6	2
245	Lenalidomide (LMID) Significantly Enhances Circulating Serum Levels of IL-2 and IL-15 Levels, NK Expansion and Activation and NK and LAK Cytotoxicity in Children with Refractory/Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Blood</i> , 2008, 112, 107-107.	0.6	4
246	Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report. <i>Blood</i> , 2008, 112, 838-838.	0.6	4
247	Quantitative Proteomic Identification of Novel Diagnostic Biomarkers and Therapeutic Targets for Classical Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 1462-1462.	0.6	0
248	A Phase I Study of <sup>90</sup> Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin's Lymphoma: A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2007, 13, 5652s-5660s.	3.2	31
249	Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i> , 2007, 109, 2736-2743.	0.6	334
250	Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <i>Blood</i> , 2007, 109, 2773-2780.	0.6	382
251	Allogeneic Bone Marrow Transplantation in First Remission for Children with Ultra-high-risk Features of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study Report. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 218-227.	2.0	60
252	A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2007, 49, 306-312.	0.8	48

#	ARTICLE	IF	CITATIONS
253	Human natural killer cells in health and disease. <i>Pediatric Blood and Cancer</i> , 2007, 49, 615-623.	0.8	30
254	Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. <i>British Journal of Haematology</i> , 2007, 138, 506-512.	1.2	26
255	Immunophenotypic and Proteomic Characterization of Cord Blood (CB) CD56dim Versus Peripheral Blood (PB) CD56dim NK Cells.. <i>Blood</i> , 2007, 110, 3879-3879.	0.6	0
256	A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing Sibling Allografting for Acute Lymphoblastic Leukemia in First or Second Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 438-453.	2.0	182
257	Characterization of Cord Blood Natural Killer and Lymphokine Activated Killer Lymphocytes Following Ex Vivo Cellular Engineering. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 608-622.	2.0	32
258	Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months. <i>Journal of Clinical Oncology</i> , 2006, 24, 145-151.	0.8	93
259	Results of the Cord Blood Transplantation (COBLT) Study unrelated donor banking program. <i>Transfusion</i> , 2005, 45, 842-855.	0.8	87
260	Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report. <i>Transfusion</i> , 2005, 45, 856-866.	0.8	95
261	Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. <i>British Journal of Haematology</i> , 2005, 128, 49-58.	1.2	29
262	Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. <i>Pediatric Blood and Cancer</i> , 2005, 44, 338-347.	0.8	111
263	Childhood and adolescent non-Hodgkin lymphoma: New insights in biology and critical challenges for the future. <i>Pediatric Blood and Cancer</i> , 2005, 45, 753-769.	0.8	63
264	Preliminary Results of the Safety of Immunotherapy with Gemtuzumab Ozogamicin following Reduced Intensity Allogeneic Stem Cell Transplant in Children with CD33+ Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 7164s-7170s.	3.2	44
265	A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience. <i>Clinical Cancer Research</i> , 2005, 11, 2644-2650.	3.2	19
266	Cord Blood Immunology and Stem Cell Transplantation. <i>Human Immunology</i> , 2005, 66, 431-446.	1.2	65
267	Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future Challenges. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 403-422.	2.0	38
268	Differential Gene Expression Patterns by Oligonucleotide Microarray of Basal versus Lipopolysaccharide-Activated Monocytes from Cord Blood versus Adult Peripheral Blood. <i>Journal of Immunology</i> , 2004, 172, 5870-5879.	0.4	43
269	Tumour lysis syndrome: new therapeutic strategies and classification. <i>British Journal of Haematology</i> , 2004, 127, 3-11.	1.2	809
270	A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 246-258.	2.0	92

#	ARTICLE	IF	CITATIONS
271	cDNA Microarray Analysis of Genes Associated with NPM-ALK Overexpression in Anaplastic Large Cell Lymphomas.. Blood, 2004, 104, 2269-2269.	0.6	3
272	Reduced Intensity (RI) Allogeneic Stem Cell Transplantation (ALLOSCT) with Umbilical Cord Blood (UCB) in Pediatric Patients with Malignant and Non-Malignant Diseases.. Blood, 2004, 104, 5167-5167.	0.6	1
273	Preliminary Results of Reduced Intensity Allogeneic Stem Cell Transplantation (RI ALLOSCT) followed by a Dose Escalation of Targeted Consolidative Immunotherapy with Gemtuzumab Ozogamicin (GO) in Pediatric Recipients with CD33+ AML.. Blood, 2004, 104, 4510-4510.	0.6	0
274	Childhood and adolescent large-cell lymphoma (LCL): A review of the children's cancer group experience. American Journal of Hematology, 2003, 72, 53-63.	2.0	46
275	Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience*. British Journal of Haematology, 2003, 120, 660-670.	1.2	153
276	Recombinant Urate Oxidase (Rasburicase): A New Targeted Therapy for Prophylaxis and Treatment of Patients with Hematologic Malignancies at Risk of Tumor Lysis Syndrome. Clinical Lymphoma and Myeloma, 2003, 3, 233-234.	2.1	5
277	A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood, 2003, 101, 2476-2482.	0.6	155
278	B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children's cancer group report. Clinical Advances in Hematology and Oncology, 2003, 1, 314-7.	0.3	28
279	Prevention and Treatment of Hyperuricemia in Hematological Malignancies. Clinical Lymphoma and Myeloma, 2002, 3, S26-S31.	2.1	27
280	Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7 Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Experimental Hematology, 2002, 30, 245-251.	0.2	45
281	Prospective Randomized Trial Between Two Doses of Granulocyte Colony-Stimulating Factor After Ifosfamide, Carboplatin, and Etoposide in Children With Recurrent or Refractory Solid Tumors: A Children's Cancer Group Report. The American Journal of Pediatric Hematology/Oncology, 2001, 23, 30-38.	1.3	49
282	A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood, 2001, 97, 2998-3003.	0.6	431
283	Large-Cell Lymphoma Arising in the Mediastinum in Children and Adolescents Is Associated With an Excellent Outcome: A Children's Cancer Group Report. Journal of Clinical Oncology, 2000, 18, 3845-3853.	0.8	39
284	Cord Blood Transplantation Study (COBLT): Cord Blood Bank Standard Operating Procedures. Stem Cells and Development, 1998, 7, 521-561.	1.0	97
285	Placental and/or Umbilical Cord Blood: An Alternative Source of Hematopoietic Stem Cells for Transplantation. Blood, 1997, 90, 4665-4678.	0.6	380
286	A phase II trial of human recombinant Interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A children's cancer group study. Cancer, 1995, 75, 2959-2965.	2.0	59
287	Innovations in Human Stem Cell Research: A Holy Grail for Regenerative Medicine. , 0, ,		1